Caris Life Sciences, Inc. provides diagnostics and anatomic pathology services. The company is headquartered in Irving, Texas and currently employs 1,846 full-time employees. The company went IPO on 2025-06-18. The firm develops and commercializes solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale. Its entire portfolio of precision medicine solutions is designed to benefit patients, with an initial focus on oncology, and serves the clinical, academic, and biopharma markets. Its platform is purpose-built to leverage the convergence of next-generation sequencing (NGS), artificial intelligence (AI) and machine learning (ML) technologies, and high-performance computing. Its purpose-built, proprietary multi-omic profiling solutions capture and analyze molecular information from tissue and blood in a comprehensive manner. Its services for biopharma companies include prospective and retrospective profiling services, and companion diagnostics development.
Mr. David Halbert es el Chairman of the Board de Caris Life Sciences Inc, se unió a la empresa desde 2008.
¿Qué tal es el rendimiento del precio de la acción CAI?
El precio actual de CAI es de $17.8, ha aumentado un 0.16% en el último día de negociación.
¿Cuáles son los temas de negocio principales o las industrias de Caris Life Sciences Inc?
Caris Life Sciences Inc pertenece a la industria Biotechnology y el sector es Health Care
¿Cuál es la capitalización bursátil de Caris Life Sciences Inc?
La capitalización bursátil actual de Caris Life Sciences Inc es $5.0B
¿Es Caris Life Sciences Inc una compra, una venta o una posición de mantener?
Según los analistas de Wall Street, 15 analistas han realizado calificaciones de análisis para Caris Life Sciences Inc, incluyendo 5 fuerte compra, 6 compra, 2 mantener, 0 venta, y 5 fuerte venta